title: Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
abstract: BACKGROUND
  Imatinib is a new major treatment in chronic myeloid leukemia.
  
  
  OBJECTIVE
  To study the cutaneous reactions induced by imatinib.
  
  
  METHODS
  All inpatients and outpatients with Philadelphia chromosome-positive leukemia treated by imatinib were included in this prospective study. Clinical features, pathologic findings, evolution of each case, and analysis of potential risk factors were recorded.
  
  
  RESULTS
  A total of 54 patients were included, 48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 rashes, 35 edemas, and 22 pruritus. The rash was severe in 5 patients, resulting in temporary interruption of treatment in 3. Highly significant relationships were observed between the daily dose of imatinib and both rashes and edema. In a multivariate analysis, female sex and the daily dose of imatinib were independent risk factors for the development of rashes.
  
  
  CONCLUSIONS
  Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent.
authors.affiliation: Department of Dermatology, Henri-Mondor Hospital (Assistance Publique Hopitaux de Paris), Paris XII University, F-94010 Paris Cedex, France.
authors.forename: Laurence
authors.initials: L
authors.lastname: Valeyrie
authors.forename: Sylvie
authors.initials: S
authors.lastname: Bastuji-Garin
authors.forename: Jean
authors.initials: J
authors.lastname: Revuz
authors.forename: Nicolas
authors.initials: N
authors.lastname: Bachot
authors.forename: Janine
authors.initials: J
authors.lastname: Wechsler
authors.forename: Patrice
authors.initials: P
authors.lastname: Berthaud
authors.forename: Michel
authors.initials: M
authors.lastname: Tulliez
authors.forename: Stéphane
authors.initials: S
authors.lastname: Giraudier
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology*; D004487:Edema / Q000139:chemically induced; D005076:Exanthema / Q000139:chemically induced; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D010879:Piperazines / Q000009:adverse effects*; D011446:Prospective Studies; D011537:Pruritus / Q000139:chemically induced; D011743:Pyrimidines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate